Today the New Mexico Medical Cannabis Program has almost 70,000 registered participants with over 75 dispensaries operated by 35 licensed non-profit producers (LNPP’s) now growing 14,550. The Medical Cannabis Program (MCP) was created in 2007, as the Lynn and Erin Compassionate Use Act, under chapter 210 Senate Bill 523. New Mexico’s medical cannabis history started in 1978, after public hearings the legislature enacted H.B. 329, the nation’s first law recognizing the medical value of cannabis…the first law.
Check out these highlights of the year that was 2018.
2018 started with shocking news for the cannabis community when Jeff Sessions rescinded the Cole Memo that provided a layer of protection to medical cannabis patients and programs. In his memo he stated that the decision to repeal was because of “Congress’s determination that marijuana is a dangerous drug and that marijuana activity is a serious crime.”
While it first appeared that the rescission of the Cole memo would be a blow to the cannabis industry, the effects have been more positive than many would have anticipated. Sessions’ decision initially created uncertainty, raised fears of incipient law enforcement actions, and spooked investors, but as it became clear that state attorneys general largely would continue to abide by the terms set forth by the Cole Memo, panic abated.
Industry leaders recognized the need for accountability and compliance to stay on the right side of federal prosecutors, which was a positive development for patients and consumers. Rescinding the memo once again laid bare the unsustainable tension between state and federal laws and prompted important discussions about cannabis reform at the federal level, including pronouncements from politicians of all stripes about the need to respect states’ decisions regarding cannabis laws.
The DEA Removes Misinformation about Cannabis from its Website.
For years, the U.S. Drug Enforcement Agency maintained false and misleading information about cannabis on its website. In December 2016, ASA submitted an Information Quality Act (IQA) petition to compel the DEA to stop disseminating inaccurate information to the public. In January 2018, Americans For Safe Access received a letter from the DEA acknowledging that the materials ASA raised concerns about were removed from the DEA website but asserting that this was due to a “regular review process” rather than the IQA petition.
The removal of inaccurate materials is a significant development, because elected officials rely upon the DEA to provide fact-based information about medical cannabis to inform policy decisions. With misinformation about the gateway drug hypothesis, permanent cognitive declines, and lung cancer off the DEA’s website, politicians have access to higher quality data and cannot take political cover behind pro-prohibition falsehoods.
As New Mexico state politics got rolling in Santa Fe for the 30 day session at the Roundhouse in 2018 we saw big pharma muscle their way into the state medical cannabis industry. House Bill 139 “Marijuana Derivative Drug Exemptions” was passed into law for GW Pharmaceuticals and was sponsored Rep. Youngblood and Rep. Deborah Armstrong. Pleas from patient advocates and the patient community for other legislation to expand and protect the medical cannabis program were ignored by state legislators. Nor did we see any lawmakers act on recommendations made by Doctors on the state’s medical cannabis advisory board from 2017 during the 30 day 2018 legislative session.
At the end of February the medical cannabis advocacy organization, Americans for Safe Access, released its annual report entitled “Medical Marijuana Access in the United States: A Patient-Focused Analysis of the Patchwork of State Laws.” The report examines the status of states that have passed medical marijuana laws and grades them on a 500 point scale. Forty-six states and three territories have some form of medical cannabis program, meaning approximately 95% of the American population lives in a state with some form of medical cannabis law.
This ASA report is an important management tool for those of us who are serious about improving medical cannabis programs. "With the ongoing opioid crisis we must look for solutions that can help reduce the number of preventable deaths. Research has shown that medical cannabis can play a significant role in mitigating the opioid epidemic. Americans for Safe Access' model legislation and regulations take the guesswork out of drafting laws that help patients, including those with chronic pain,” said Pennsylvania State Senator Mike Folmer. “Being able to compare my state's progress with the grades of other state is incredibly helpful in creating a roadmap for improvement."
March started out with the years best event with the 2018 New Mexico Medical Cannabis Conference that was presented by The Verdes Foundation. Top medical cannabis industry experts like Mara Gordon, Dr. Dustin Sulak, Dr. Bonni Goldstein, and Dr. Debra Kimless came to Albuquerque to share their expertise with our community.
[ Related Article: ‘New Mexico Medical Cannabis Conference 2017: Conference Resources and Video Guides’ ]
April started with some big news for cannabis policy in Albuquerque when on Monday evening, April 2nd 2018 the Albuquerque City Council voted to approve the proposed Ordinance O-18-12; "Amending The Criminal Code Of Albuquerque To Remove Marijuana Offenses And Related Penalties; Amending Chapter Eleven Of The Code Of Ordinances To Establish Civil Penalties For Possession Of One Ounce Or Less Of Marijuana Or Marijuana Paraphernalia" for the decriminalization of cannabis which was signed into law by Albuquerque’s Mayor Keller.
Also in the first week of April the New Mexico Department of Health released a Medical Cannabis Program Assessment. More than three-fourths (83%) of the program participants list Post-Traumatic Stress Disorder (49.1%) or Severe Chronic Pain (33.3%) as a qualifying condition and Patients must meet at least one of the 21 conditions for a medical cannabis card. There is no cost to apply for a medical cannabis card in New Mexico and providers can accept health insurance. Any New Mexico practitioner with prescribing authority can sign a certification for a patient with a qualifying condition. The certifying provider is required to have provider/patient relationship.
[ Related Article: ‘Talking to your Doctor about Medical Cannabis’ ]
CNN chief medical correspondent Dr. Sanjay Gupta provided an in-depth look at potential medical cannabis has as both an alternative to opioids in treating pain and in ending opioid addiction. WEED 4: POT VERSUS PILLS aired on CNN, Sunday, April 29th 2018.
We also learned in April how, in New Mexico, we have families unjustly being denied to allow their child to use medical cannabis while at school.
We've come a long way since cannabis was first decriminalized in Oregon in 1973 and then in New Mexico; medical cannabis history started in 1978, after public hearings the legislature enacted H.B. 329, the nation’s first law recognizing the medical value of cannabis…the first law. This now being the 10th year for New Mexico’s Medical Cannabis Program (MCP) that was created in 2007, as the Lynn and Erin Compassionate Use Act, under chapter 210 Senate Bill 523.
Safe Access to medical cannabis for those patients who do or will benefit most from medical cannabis treatments; still need to overcome political, social and legal barriers with advocacy by creating policies that improve safe access to medical cannabis for patients - and that means at school too.
Proposed 2019 NM Legislation: AN ACT: Safe Access To Medical Cannabis in School
The Rohrabacher-Blumenauer Amendment prohibits the use of federal funds to interfere with the implementation of state laws that authorize the use, distribution, possession, or cultivation of medical marijuana. Given that cannabis is still classified as a Schedule 1 drug under the Controlled Substances Act, this language provides critical legal protections for medical cannabis patients and the people who produce their medicine. From 2003-2012, the amendment was voted down six times. The amendment was successfully added to the Commerce, Justice, and Science (CJS) Appropriations bill for the first time in 2014 and has been renewed in some manner each year since.
In May 2018, the House Appropriate Committee approved inclusion of the amendment language in the base text of the CJS appropriations bill. In addition to signaling broad support for the language, it’s addition to the base text helps to ensure that these critical protections will remain in place each time the appropriations bill is voted on moving forward. It’s crucially important that your elected representatives understand the importance of ensuring that medical cannabis patients receive necessary protections from prosecution under federal law. To learn how to lobby your legislators effectively and further advocate for medical cannabis patients, register for the 2019 National Medical Cannabis Unity Conference today!
Medical Cannabis Policies Encourage Lower Prescription Opioid Use.
Opioid-related mortality rose by almost 320% between 2000 and 2015. In May 2018, the Journal of the American Medical Association (JAMA) published an original investigation into the relationship between U.S. state medical cannabis laws and the prescription of opioids in the Medicare Part D population. The longitudinal analysis found that prescriptions filled for all opioids in the Medicare Part D population fell by 2.11 million daily doses per year when a state instituted any medical cannabis law; prescriptions for all opioids in this population fell by 3.742 million daily doses per year when medical cannabis dispensaries opened in a state.
The JAMA investigation concluded that medical cannabis policies are an effective method by which to encourage lower prescription opioid use and an effective harm reduction tool in the fight against the opioid epidemic. Through our End Pain, Not Lives campaign, ASA will continue to advocate forcefully for the expansion of medical cannabis programs to make cannabis an alternative to opioids for those suffering from severe pain and for those battling opioid use disorder.
The New Mexico Department of Health’s (NMDOH) Medical Cannabis Program launched a new version of the patient application, with changes that help both patients and certifying practitioners.
The application is reduced from four pages to two and can be completed electronically then printed for signing. Certifying practitioners must now send medical records with the proof of provider visit form instead of having to write lengthy explanations as required on the previous applications. Additional changes include easier-to-read font, and instruction pages for applicants and certifying practitioners.
The FDA Approves Epidiolex.
GW Pharmaceuticals’ Epidiolex, an oral solution containing cannabidiol (CBD), received FDA approval for two rare seizure disorders in June 2018. While synthetic cannabinoid medications already exist, Epidiolex is the first cannabinoid medication to be derived directly from the cannabis plant. Unlike most medical cannabis in the United States, FDA-approved medications like Epidiolex can be prescribed by doctors, purchased in pharmacies, and covered by insurance. Epidiolex signified the first time a cannabis derived medication was approved by the FDA, potentially opening the door for more cannabis-derived medicines. If you need more information to better understand cannabis therapeutics or to better navigate your state’s medical cannabis program, check out ASA’s Cannabis Care Certification program for patients and caregivers!
In July 2018, the New York State Department of Health issued emergency regulations adding any condition for which an opioid could be prescribed as a qualifying condition for medical cannabis and further expanding the list of qualifying conditions to include opioid use disorder. That same day, the health department filed a Notice of Proposed Rulemaking to make the new regulations permanent. The next month, Illinois also took a huge step forward when Gov. Rauner signed SB 336 into law, which allows certain individuals who have been given an opioid prescription to trade that prescription in for a medical cannabis card and allows doctors to authorize the use of medical cannabis immediately for any patient who qualifies for a prescription for opioid medication. In both states, the new rules made accessing medical cannabis easier and faster to ensure that patients’ suffering is not needlessly prolonged.
New York and Illinois are setting examples that other states should follow! Please consider donating directly to ASA’s End Pain, Not Lives campaign to ensure that we can continue to educate legislators about the need to make medical cannabis a tool in the fight to stop the opioid epidemic.
In New Mexico we saw state health officials are warn medical cannabis dispensaries against selling cannabidiol produced outside of New Mexico or from hemp plants grown outside the state.
The Santa Fe New Mexican reported that the Medical Cannabis Program director Kenny Vigil wrote to dispensaries June 7 2018 that the practice is "in violation of the Lynn and Erin Compassionate Use Act and must cease."
The act forbids businesses licensed in New Mexico from bringing cannabis or cannabis-derived products into New Mexico. The New Mexico Department of Health says cannabidiol, or CBD, falls into that category.
As August got underway, Republican Illinois Gov. Bruce Rauner signed a law requiring public schools to allow parents to administer medical cannabis at school to eligible children.
For the second time now, Safe Access New Mexico provided a petition to the Department of Health to add Autism Spectrum Disorders into the New Mexico Medical Cannabis Program, for the September 2018 meeting. The Safe Access New Mexico April 2017 Petition was approved by the Doctors on the Advisory Board by a 3-0 Vote and the Secretary decline to add ASD into the program.
Petition Requesting The Inclusion Of A New Medical Condition: Autism Spectrum Disorders can be viewed here.
On Friday, September 7th 2018 at the New Mexico Medical Cannabis Advisory Board Hearing, the Chair of the Advisory Board, Dr. Laura Brown announced that while Secretary Gallagher declined to add Sleep Disorders into the medical cannabis program, the Secretary did ADD Obstructive Sleep Apnea as a New Qualifying Condition. Safe Access New Mexico, a Chapter of American For Safe Access successfully provided the Petition to add the new condition in November 2017. The New Mexico Medical Cannabis Program now has 22 Qualifying Health Conditions.
DEA reschedules CBD in Epidiolex, a cannabis-derived drug, classified as a schedule 5.
The Drug Enforcement Administration rescheduled Epidiolex, paving the way for GW Pharmaceuticals to start selling the first FDA-approved drug derived from cannabis, but stopped short of reclassifying all cannabidiol products. The rescheduling applies to CBD containing no more than 0.1 percent THC, in FDA-approved drug products.
The Food and Drug Administration in June approved Epidiolex, which is derived from cannabidiol, or CBD, a molecule contained in the cannabis plant. This forced the DEA to consider how it would classify Epidiolex since cannabis (marijuana) is considered a schedule 1 drug, which it defines as having no currently accepted medical use and a high potential for abuse.
October 2018 The Food and Drug Administration (FDA) announced that it was seeking public comments on cannabis and cannabis-related policies. The request for feedback and comments came as officials prepared to write an official statement for the World Health Organization (WHO), which is still considering changing its recommendations on international cannabis laws.
On October 25th we saw two mothers unite at the Roundhouse to advocate for allowing medical cannabis in schools. Lindsey Sledge, whose daughter Paloma was attending Albuquerque Public School and Tisha Brick whose son Anthony Brick was attending Estancia Municipal Schools, in emotional pleas both mothers told members of the Legislative Human Health and Services interim committee how medical cannabis is the only medication that works and both say it’s what keeps their children alive. And they received support from the Legislative Human Health and Services interim committee, which is going to be pushing new legislation.
Also in October 2018, the global standards organization ASTM International and the ASA-cofounded center of excellence International Cannabis and Cannabinoid Institute (ICCI) signed a memorandum of understanding to work together on standards for the cannabis industry.
ICCI is based in the Czech Republic and is the first European organization to join ASTM’s Committee D37 on Cannabis. ICCI is licensed to offer Americans For Safe Access’ Patient Focused Certification (PFC) program globally and will be coordinating PFC resources and efforts with ASTM International to meet the pressing need for international cannabis standards relating to cultivation and use in cosmetics, foods, and extracts as well as medicinal and laboratory-related standards. ICCI’s participation will help the committee identify gaps in knowledge, prevent the duplication of work, and strengthen the development of robust international standards that protect patients, consumers, and businesses. We encourage you to learn more about our Patient Focused Certification program, which patients, health care providers, companies, and regulators can depend on to identify reliable, high-quality medical cannabis, businesses, products, and services.
The hard work of advocates, activists, patients, ASA, and other reform-oriented organizations led to the expansion of medical cannabis in Missouri, Oklahoma, and Utah in November 2018. As a result, 33 U.S. states now have a comprehensive medical cannabis program. Before their respective election days, Oklahoma did not have a medical cannabis program and Missouri and Utah had very restrictive low-THC, high-CBD programs. Voters in all three states sent a message about the need for safe and legal access to medical cannabis.
Politicians and bureaucrats in Oklahoma and Utah have tried to limit the reach of the voter-passed initiatives legalizing medical cannabis in those states, but ASA has been fighting back to ensure that the will of the people is heard and that the best possible medical programs are implemented. Momentum continues to build for the further expansion of medical and adult-use regimes throughout the United States. If you would like to help advocate for your state, check out ASA’s Advocate Resources.
Also in November, New Mexico state District Court Judge Thomson ruled on November 1st 2018, that the state Department of Health’s Medical Cannabis Program 450-plant limit on Licensed Producers is arbitrary and capricious and has no factual basis, as reported by the Albuquerque Journal.
District Court Judge David Thomson issued his 60-page ruling Thursday and is giving the Department of Health’s Medical Cannabis Program 120 days (by March 1st 2019) to come up with a new rules on growing plant limits. He wrote that the department has been “impeding the purpose” of New Mexico’s medical cannabis program statute, thus the sole purpose of the law has not been followed by the Department.
“Section 2. PURPOSE OF ACT.--The purpose of the Lynn and Erin Compassionate Use Act is to allow the beneficial use of medical cannabis in a regulated system for alleviating symptoms caused by debilitating medical conditions and their medical treatments.”
And some of the best news of the year, Attorney General Jeff Sessions Becomes Former Attorney General Jeff Sessions!
Former Senator Jeff Sessions (R-AL) was President Trump’s first pick for attorney general and served in that capacity until he was unceremoniously fired in November 2018. Advocates and industry leaders alike celebrated the departure of one of the most ardent opponents of cannabis in recent political memory. Jeff Sessions has been on the wrong side of history regarding cannabis for years.
He was a vocal proponent of continuing and expanding the disastrous War on Drugs, tried to use federal muscle to intimidate states experimenting with cannabis reforms, and supported harsher sentences for low-level drug offenses even as a push for sentencing reform and ending mass incarceration gained bipartisan support throughout the country. He famously said, “I thought those guys [the Ku Klux Klan] were OK until I learned they smoked pot” and “Good people don’t smoke marijuana,” and he was a barrier to efforts to expand the availability of cannabis and cannabis products for medical research.
While few politicians are as vocally hostile to cannabis reform efforts as Jeff Sessions, the battle is far from won at the federal level.
On Friday December 7 2018, the Medical Cannabis Advisory Board (MCAB) met and voted to approve Petition 2018-004: Add Alzheimer's Disease as an Approved Condition and Petition 2017-039: Add Degenerative Neurological Disorders And Neuroprotective Applications as Approved Conditions. Petition 2017-039 was submitted by Safe Access New Mexico, and can be viewed here.
2018 Farm Bill Legalizes Industrial Hemp and Extracts.
Congress made history in December 2018 when the House and Senate voted to permanently remove industrial hemp – and extracts derived from industrial hemp – from the schedule of controlled substances. Industrial hemp plants contain no more than 0.3% THC and can be used in tens of thousands of ways across a range of industries, including medicine, manufacturing, construction, and food & beverage. Importantly, some varieties of industrial hemp are high in cannabidiol (CBD), a non-intoxicating cannabinoid with a number of promising medicinal uses.
Among the many benefits of Congress’ move to treat industrial hemp like other agricultural commodities is the fact that therapeutic cannabinoids and terpenes will be more available and accessible once the bill has been signed into law. However, patients and consumers must remain vigilant to ensure that any hemp and hemp-derived products they purchase for consumption or topical application were cultivated and processed or manufactured in accordance with standards as stringent as the Patient Focused Certification standards ASA developed around cultivation, manufacturing, distribution, and laboratory practices to ensure products are safe, pure, and appropriately labeled.
December came to a close in New Mexico with the Santa Fe New Mexican reporting that Ultra Health, New Mexico’s largest producer and seller of medical cannabis, is challenging the way the state regulates makers of edibles, salves, lotions and other cannabis-infused products for sale in dispensaries. This has great potential to cause serious HARM to Safe Access to medical cannabis products for patients in New Mexico and other LNPP's! This lawsuit could also prevent: the creation of Patient Run Collectives, prevent a manufacturer business model that would process patient Personal Production License (PPL) medicine or medicine from created Collectives, prevent Manufacturers from being licensed to grow their own plants for specialized medical cannabis medicines, and have a huge and negative effect on any future Hemp CBD medical cannabis business becoming legit.
Lawmakers in the Roundhouse are preparing legislation for the upcoming 2019 Regular Session and now is the time to speak out and advocate for the changes the Patient’s Medical Cannabis Program needs as it has been severely neglected by the state over the last several years.
Legislators in the Roundhouse are projected to have $1.2 billion coming in for the new budget year, so there is absolutely no need to fast track recreational cannabis legalization in New Mexico for 2019. Lawmakers cite the need for more money for education, and always mention all the money Colorado has coming in from Cannabis legalization for education - Guess what, we already spend more per student in public schools than Colorado does, New Mexico has a money management issues going on and that needs to be addressed before tackling Recreational Legalization.
Governor-elect Michelle Lujan Grisham should be first and foremost talking about fixing the medical cannabis program to allow Safe Access to Medical Cannabis at Schools and end the discrimination there.
Throughout the course of the Martinez administration, the Governor has had a “do nothing” approach to the medical cannabis program which in itself has been destructive to it over the years. As the program grew in size with more and more people using medical cannabis nothing has been done to all for the a fundamental aspect of the law to maintain itself - “adequate supply”. The medical cannabis program has close to 65,000 people in it and the producers grow 14,500 cannabis plants thus there is less than one third of a plant per person in the program. And it takes a cannabis plant in ideal conditions 21 to 28 weeks to grow for harvest.
The proposed recreational cannabis bill will allow for the current medical cannabis producers to have a dual licensure option to be recreational cannabis businesses when they should be kept completely separate. And the proposed bill further state that only ⅓ of cannabis plants are kept for the medical cannabis program which is not near enough. And none of the the current legislators pushing for recreational cannabis legalization have taken the time, in the last two years, to attend any of the Medical Cannabis Advisory Board Hearing conducted by Doctors and the Department of Health which address these issues going on in the program.
And also consider this; in other states with medical cannabis programs, after recreational legalization, all of those state medical cannabis programs have suffered...legalization has not benefited any medical cannabis program to date.
How Legalization Can Result In Isolation:
Cannabis is legal for adults 21+ in California. So why do almost 85% of cities and counties ban its sale? Why is there 25% less products available than before under medical?
While the majority of California voters supported Prop 64, the majority of cities and counties have yet to issue, or refuse to issue, licenses to cannabis businesses operating within their jurisdiction.
The city of Denver (CO) has more cannabis licenses than the state of California.
We kinda have this same exact problem in New Mexico, and not just with medical cannabis or legalization but for many crucial state policy objectives, the problem of elected officials not listening to the Voters who Elected Them.
People should come first over politics and political party platforms...
Legalization should be about Freedom and Good Health, not about how much we can tax a plant that has great Medical Value that equates to harm reduction.
Form follows Function and Policy makers in New Mexico and the US for that matter- they need to stop using the debate surrounding legalization of cannabis for recreational use to obscure the science and policy regarding the harm reduction achievements of decriminalizing cannabis and the medical use of cannabis. In today’s era of how legalization, cannabis taxation and financial profits of cannabis has spread, the distinction matters and this behoves policy makers to follow a process that achieves the greatest harm reduction.
In 2019 during the Legislative 60 day Regular Session : Pass a bill to Fix & Expand the states Neglected Medical Cannabis Program, Pass a bill Allowing Safe Access to Medical Cannabis at Schools, Enable Veterinary Doctors access to the Medical Cannabis Program, Pass Decriminalization for the State, Pass Medical Cannabis Research for UNM and get the Industrial Hemp program going with medical hemp research at NMSU for the states medical cannabis program.
Then start talking about Cannabis Recreational Use Legalization.
For policy makers, in Albuquerque, around the state and in the Roundhouse, their priority should be so it’s clear, it should be removing the public health risks of cannabis prohibition. Those public health risks, like putting people in jail for victimless crimes, jeopardizing people's access public schools and to financial aid for higher education, jeopardizing people’s employment, and exposing people to a underground market that would increase their potential to access more harmful drugs.
As you may know my name is Jason Barker, advocate for Safe Access New Mexico a Chapter of Americans For Safe Access, a freelance writer for Cannabis News Journal and a medical cannabis patient in New Mexico. With over 100,000 active members in all 50 states, ASA is the largest national member-based organization of patients, medical professionals, scientists and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research.
Legislation (below) to please review and consider emailing or mailing to your New Mexico Representatives for Medical Cannabis Program Expansion:
Find and Email Your New Mexico Legislators Any of These Bills Here: https://www.nmlegis.gov/Members/Find_My_Legislator
1. AN ACT: Safe Access To Medical Cannabis in School
Link to this Proposed Legislation: http://www.cannabisnewsjournal.co/p/proposed-2019-legislation-act-safe.html
2. MEMORIAL- LHHS Medical Cannabis Subcommittee
Link to this Proposed Legislation:
3. AN ACT: Veterinary Medicine Access To The Medical Cannabis Program
(The New Mexico Veterinary Medical Board does Support seeing this change take place.)
Link to this Proposed Legislation:
4. An Act: Relating to Amending LECUA, 2007(Was also provided at the start of the 2018 Session to the Committee Chair & other members of the LHHS Committee) (And this bill written last year, already has all the recommendations made by the DPA Task Force for the medical cannabis program.)
Link to this Proposed Legislation:
It is critically important that we remain vigilant and continue to hold our elected representatives accountable. With the support of our members and donors, Americans For Safe Access continues to fight for medical cannabis patients at all levels of government. We can not do our work without supporters like you. Please consider making a tax-deductible donation today to help sustain our important work or join us or renew your membership today to help be a part of the exciting developments to occur in 2019!
“Section 2. PURPOSE OF ACT.—The purpose of the Lynn and Erin Compassionate Use Act is to allow the beneficial use of medical cannabis in a regulated system for alleviating symptoms caused by debilitating medical conditions and their medical treatments.”
The purpose of the Lynn & Erin Compassionate Use Act, our medical cannabis program law is to allow the beneficial use of medical cannabis in a regulated system for alleviating symptoms caused by debilitating medical conditions and their medical treatments. The purpose of the act must be followed, and the state of New Mexico must stop denying these children the right to attend public school.
Resources for Policy Makers, Medical Professionals & Researchers:
Resources for Medical Professionals and Researchers
The medicinal properties of cannabis are varied given the multiplicity of physiological roles of the endocannabinoid system, a ubiquitous molecular signaling system at which compounds in cannabis have robust receptor-based actions. Here is information on medical marijuana practice policies and procedures in your locality, as well as scientific and practice ethics information.
Resources for Policy Makers
Safe Access New Mexico ~ A Chapter of Americans For Safe Access
(All Rights Reserved 04/20/2018)